HC Wainwright Raises BNGO Price Target to $11.00
ByAinvest
Monday, Aug 18, 2025 2:24 pm ET1min read
BNGO--
Bionano Genomics, a life sciences instrumentation company, specializes in genome analysis. Its Saphyr system is designed to help researchers and clinicians identify new diagnostics and therapeutic targets. Despite a 13% decline in total revenue to $6.7 million in Q2 2025 compared to Q2 2024, the company reported a significant increase in non-GAAP gross margin to 52% from 35% a year ago, indicating improved profitability [2].
The company also experienced a 17% year-over-year increase in flow cell sales, reflecting strong demand and utilization among existing customers. Non-GAAP operating expenses were reduced by 53% year-over-year, showcasing effective cost management [2]. For the full year 2025, Bionano Genomics expects revenue to be in the range of $26 million to $30 million, with Q3 revenue guidance of $6.7 million to $7.2 million [2].
Analyst Yi Chen anticipates continued growth and performance in line with the new price target. The company's strategic focus on AI-driven software development and the successful expansion of its VIA software, widely accepted as a gold standard for CNV analysis, are key drivers for future growth [1].
References:
[1] https://www.tipranks.com/news/the-fly/bionano-genomics-price-target-raised-to-11-from-10-at-h-c-wainwright-thefly
[2] https://finance.yahoo.com/news/bionano-genomics-inc-bngo-q2-072343258.html
HC Wainwright & Co. has maintained a "Buy" rating for Bionano Genomics (BNGO) and raised its price target from $10 to $11, a 10% increase. Analyst Yi Chen anticipates continued growth and performance in line with the new price target. Bionano Genomics is a life sciences instrumentation company focused on genome analysis, and its Saphyr system enables researchers and clinicians to identify new diagnostics and therapeutic targets.
H.C. Wainwright & Co. has raised its price target for Bionano Genomics (BNGO) to $11 from $10, a 10% increase, while maintaining a "Buy" rating on the shares. The analyst, Yi Chen, cited sequential revenue growth in Q2 2025 as the primary reason for the upward revision [1].Bionano Genomics, a life sciences instrumentation company, specializes in genome analysis. Its Saphyr system is designed to help researchers and clinicians identify new diagnostics and therapeutic targets. Despite a 13% decline in total revenue to $6.7 million in Q2 2025 compared to Q2 2024, the company reported a significant increase in non-GAAP gross margin to 52% from 35% a year ago, indicating improved profitability [2].
The company also experienced a 17% year-over-year increase in flow cell sales, reflecting strong demand and utilization among existing customers. Non-GAAP operating expenses were reduced by 53% year-over-year, showcasing effective cost management [2]. For the full year 2025, Bionano Genomics expects revenue to be in the range of $26 million to $30 million, with Q3 revenue guidance of $6.7 million to $7.2 million [2].
Analyst Yi Chen anticipates continued growth and performance in line with the new price target. The company's strategic focus on AI-driven software development and the successful expansion of its VIA software, widely accepted as a gold standard for CNV analysis, are key drivers for future growth [1].
References:
[1] https://www.tipranks.com/news/the-fly/bionano-genomics-price-target-raised-to-11-from-10-at-h-c-wainwright-thefly
[2] https://finance.yahoo.com/news/bionano-genomics-inc-bngo-q2-072343258.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet